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Background: The enzyme involved in regulating the size of vWF (von Willebrand factor) in plasma is ADAMTS-13
(A disintegrin and metalloprotease with thrombospondin type-1 motives). Deficient proteolysis of ULvWF (ultra
large von Willebrand factor) due to reduced ADAMTS-13 activity results in disseminated platelet-rich thrombi in the
microcirculation characteristic of thrombotic thrombocytopenic purpura. Reduced ADAMTS-13 has also been
observed in severe sepsis and is associated with poor survival. We conducted this study to detect ADAMTS-13
deficiency and its impact on in-hospital mortality in pediatric patients with severe sepsis.
Methods: Pediatric patients diagnosed with severe sepsis were recruited for the study. Baseline clinical
characteristics were noted. ADAMTS-13 antigen levels were assayed by ELISA. According to ADAMTS-13 levels,
patients were grouped as deficient and non-deficient. Comparison was done with regard to some clinical and
biological characteristics and in-hospital mortality between the two groups.
Results: A total of 80 patients were enrolled in the study. The median age of the patients was 3.1 years (Range:
0.1-15 years). ADAMTS-13 deficiency with levels less than 350 ng/dl was found in 65% patients. In patients with
ADAMTS-13 deficiency, 75.6% had low platelets of less than 150 × 109/L. In-hospital mortality was 42.3% and 35.7%
in ADAMTS-13 deficient and non-deficient group, respectively.
Conclusion: Majority of the pediatric patients admitted to hospital with severe sepsis exhibit ADAMTS-13
deficiency. ADAMTS-13 deficiency might play a role in sepsis-induced thrombocytopenia. More studies are needed
to evaluate the role of ADAMTS-13 deficiency on in-hospital mortality.
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von Willebrand factor (vWF), a multimeric protein that
mediates platelet adhesion and aggregation at sites of
vascular injury is stored in specialized storage organelles
known as Weibel-Palade bodies within the endothelial
cells and in the alpha granules of platelets [1]. It is re-
leased from the stimulated endothelium as unusually
large (UL) multimer [2,3]. ULvWF is the hyperactive
form of von Willebrand factor (vWF), having more affin-
ity for platelets favoring platelet aggregation and forma-
tion of microvascular thrombi [4,5]. This ULvWF relies* Correspondence: farheen.mahar@aku.edu
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reproduction in any medium, provided the orupon an enzyme known as ADAMTS-13 (A disintegrin
and metalloprotease with thrombospondin type-1 mo-
tives) for its cleavage and thus conversion into a less ac-
tive form [6]. Deficient proteolysis of ULvWF due to
reduced ADAMTS-13 activity results in disseminated
platelet-rich thrombi in the microcirculation seen in
thrombotic microangiopathies (TMA). Decreased levels
of ADAMTS-13 are particularly seen in TTP. Low levels
have also been observed in various other disease states
including liver disease [7], malignancy [8], systemic
lupus erythematosus [8], disseminated intravascular co-
agulation [9] and severe sepsis [10].
As elevated levels of vWF are observed in several in-
flammatory disease states including sepsis, it is believed
that normal or mildly reduced levels of ADAMTS-13td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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multimer size [10]. The net result is an accumulation of
extremely thrombogenic ULvWF on the surface of the dis-
turbed endothelium, thus propagating pathological plate-
let–endothelial interactions, which in combination with
other prothrombotic changes seen in sepsis could contrib-
ute to enhanced microvascular thrombosis, platelet con-
sumption, disseminated intravascular coagulation and
eventually multi-organ failure [11]. Reduction in ADAMTS
levels to less than 10% of normal result in clinically appar-
ent thrombosis and thrombocytopenia [12].
Many studies have evaluated the role of ADAMTS-13
in severe sepsis. In a study conducted in Japan, decreased
ADAMTS-13 activity ( less than 5%) was found in 15.6%
of patients with sepsis induced disseminated intravascular
coagulation; whereas in USA a study showed that 31% of
patients with severe sepsis had severe ADAMTS-13 defi-
ciency [11,13]. It has also been reported that deficiency of
ADAMTS-13 plays an important role in sepsis-associated
thrombocytopenia, which is seen in more than 50% of pa-
tients with sepsis and correlates with poor prognosis in
these patients [13]. Few studies have also shown that re-
duced ADAMTS-13 is associated with a poor survival rate
in sepsis [14].
Sepsis is the leading cause of death in patients of all
age groups presenting to the emergency of our hospital
(23%; 95% CI 19-26%) [15] A worldwide systemic ana-
lysis carried out in 2008 indicated that Pakistan was
among the five countries with very high pediatric mor-
tality and sepsis accounted for 6% of all neonatal deaths
[16]. Thus, the burden of sepsis and sepsis-related
deaths is very high nationwide and preventive strategies
are needed to decrease sepsis associated morbidity and
mortality. Based on the background of association of
ADAMTS-13 with sepsis, we conducted this study to
detect ADAMTS-13 deficiency in pediatric patients with
severe sepsis. Furthermore, we correlated ADAMTS-13
deficiency with sepsis associated thrombocytopenia and
in-hospital mortality.
Methods
Study design and setting
The study was conducted in the section of Haematology,
Department of Pathology and Microbiology, The Aga
Khan University Hospital, Karachi. This was a cross-
sectional study extending over one year from February
2010 to January 2011.
Patient selection
80 pediatric patients admitted to The Aga Khan Univer-
sity Hospital and diagnosed as having severe sepsis
according to the guidelines of the society of Critical Care
Medicine Consensus Conference Committee were
recruited for the study [17]. In short, selected patientsmet at least 3 out of the 4 systemic inflammatory re-
sponse criteria (core temperature >38.5°C or <36°C;
tachycardia >2 SD above normal for age; mean respira-
tory rate >2 SD above normal for age and leukocyte
count elevated or depressed for age) in the presence of a
known or a suspected infection proven by one or more
of the following findings: bacteremia, purulent sputum;
presence of clinical signs that are associated with high
risk for infection such as cholangitis or peritonitis; de-
tection of pathogenic microorganisms or white blood
cells in a normally sterile body fluid such as urine or joint
fluid and radiological evidence of pneumonia alongwith
one of the following: cardiovascular organ dysfunction,
acute respiratory distress syndrome or two or more organ
dysfunctions (respiratory, renal, neurological, hematological
or hepatic) [17].
Patients with a known thrombotic or bleeding dis-
order, patients receiving transfusion of blood products
within a week of sample collection and those with end
stage liver disease were excluded from the study.
Consent
Written informed consent was obtained from the par-
ent/guardian of the patient.
Sample collection
Three milliliter of venous blood sample was taken from
every patient into tubes containing 3.2% sodium citrate
anticoagulant for analysis of ADAMTS-13 antigen levels.
Platelet poor plasma was obtained after centrifugation of
samples. Plasma samples were labeled and kept at −80°C
until analysis.
ADAMTS-13 analysis
ADAMTS-13 antigen levels were performed on platelet
poor plasma sample collected in citrate by IMUBINDW
ADAMTS-13 ELISA (American Diagnostica Inc, USA).
ADAMTS-13 antigen level of less than 350 ng/dl was
taken as deficient as defined by the manufacturer. Pa-
tients were categorized in two groups according to the
ADAMTS-13 level as deficient and non-deficient. Com-
parison was done with regard to some clinical and bio-
logical characteristics and in-hospital mortality between
the two groups.
Statistical analysis
Data was entered and analyzed using SPSS (statistical
package for social Sciences; Chicago Inc, USA) version
19.0. Statistical tests used for comparison of clinical
characteristics included Mann–Whitney U test, Fisher
exact test and Chi-square test depending on the scale of
measurement. A p-value of <0.05 was considered statis-
tically significant. Kaplan-Meier method was used for
evaluating survival.
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The study was approved by the Ethical review commit-
tee of The Aga Khan University Hospital. (ERC approval
Number: 1598-Path-ERC-2010).
Results
A total of 80 patients were included in the study. The
median age of the patients was 3.1 years (Range: 0.1-15 -
years). There were 45 (56.25%) males and 35 (43.75%)
females. ADAMTS-13 deficiency with levels less than
350 ng/dl was found in 52 (65%) patients, whereas 28
(35%) were not deficient. Microbiologically defined in-
fection was present in 48 (60%) patients. The clinical
characteristics were compared and do not appear to be
different between the two groups (Table 1).
Overall, 37 (46.2%) patients were found to have plate-
lets of less than 150 × 109/L. Among those who had low
platelets, 28 (75.6%) patients were in the ADAMTS-13
deficient group.
The mean duration of hospitalization was 12.4 days in
patients with ADAMTS-13 deficiency, while it was 8.8 -
days in the non-deficient group. The difference was not
statistically significant.
In-hospital mortality was seen in thirty-two (40%) pa-
tients. Forty-two (52.5%) of the patients were discharged
from the hospital in stable condition, while 6 (7.5%)
were shifted to another hospital. Out of the total 32 pa-
tients who expired, 22 (42.3%) had ADAMTS-13 defi-
ciency whereas 10 (35.7%) were not deficient. The
cumulative survival of the patients between the two
groups using Kaplan-Meire is shown in Figure 1. The
difference was not statistically significant.
Discussion
ADAMTS13 plays an important role in the processing of
vWF. Primary ADAMTS13 deficiency caused by defects
in the ADAMTS13 gene has been shown to cause Throm-
botic thrombocytopenic purpura (TTP) [18]. TTP is aTable 1 Characteristics of patients in ADAMTS-13 deficient an
Characteristics ADAMTS-13 deficient group (n=









APTT (sec) 42fatal thrombotic microangiopathic disease if emergency
plasma pheresis is not started [19]. This shows the import-
ance of the physiologic role of ADAMTS13-catalyzed
cleavage of the unusually large vWF multimers in humans.
While looking into the role of ADAMTS13 in common
diseases associated with thrombotic microangiopathies, it
was found that severe secondary ADAMTS13 deficiency
is also present in patients with sepsis, connective tissue
diseases, liver cirrhosis and acute inflammation [7,20].
Severe sepsis and septic shock are the consequence of
an uncontrolled and extensive inflammatory response to
infection which is associated with systemic activation of
a number of host defense mechanisms [21]. Decreased
ADAMTS-13 in sepsis has been suggested to be due to
several potential mechanisms. These mechanisms in-
clude consumption of ADAMTS-13 due to on-going
cleavage of excessively secreted ULvWF from activated
endothelium during sepsis; inhibition of ADAMTS-13
by inflammatory cytokines such as interleukin −6 (IL-6) ;
cleavage of ADAMTS-13 by proteases released from
neutrophils during inflammatory conditions and last but
not the least functional inactivation by coagulation pro-
teinases [11,22]. Deficiency of ADAMTS-13 results in
microthrombi in the circulation resulting in ischemia and
end-organ damage.
Decreased levels have been observed in healthy volun-
teers following endotoxin infusion [23], in inflammatory
diseases, and also in thrombocytopenia associated with se-
vere sepsis [8,11,24]. Our results revealed that pediatric
patients with severe sepsis had a high incidence of
ADAMTS-13 deficiency. In our study population 65%
of the patients were found to be deficient in ADAMTS-
13. Our results match with the results reported by
Scully et al. who also reported a high frequency of
ADAMTS-13 deficiency in 48 children admitted to
neonatal or pediatric intensive care unit. In this study
64% of the children showed reduced ADAMTS-13
levels [25]. Moore et al. also reported in his study ad non-deficient group























Figure 1 Cumulative survival of patients with and without ADAMTS-13 Deficiency.
Karim et al. BMC Pediatrics 2013, 13:44 Page 4 of 5
http://www.biomedcentral.com/1471-2431/13/44similar frequency of ADAMTS-13 deficiency seen in
60% patients suffering from disseminated intravascular
coagulation [26].
Our results revealed that majority of the septic pa-
tients with thrombocytopenia were in the ADAMTS-13
deficient group. A study from USA by Nguyen et al.,
conducted on 21 pediatric patients with severe sepsis
also concluded that ADAMTS-13 deficiency was associ-
ated with thrombocytopenia [13]. It is hypothesized that
sepsis-associated thrombocytopenia is a result of platelet
consumption due to aggregation of platelets in the
microcirculation and thrombotic microangiopathy due
to incomplete cleavage of ULVWF multimers as a conse-
quence of ADAMTS-13 deficiency. Sepsis-associated
thrombocytopenia has been correlated with poor prog-
nosis [27].
Studies have shown that patients with low ADAMTS-
13 activity have a poor survival. Hyun J et al. reported
poor survival of patients with low ADAMTS-13 activity
than patients with higher activity (p-value 0.0477) [14].
One of the studies showed that ADAMTS-13 activity
was significantly lower in patients with severe sepsis and
patients above the median of ADAMTS-13 activity
presented a higher survival compared with those below
the median activity [15]. In our study, survival of pa-
tients with and without ADAMTS-13 deficiency was not
statistically significant. Few patients in our study (7.5%)
were either shifted to another hospital due to unavail-
ability of intensive care unit bed or left against medical
advice. All of them were ADAMTS-13 deficient and
were unstable. Since, we do not know about the mortal-
ity in these patients, they were not included in the ana-
lysis. Inclusion of these patients in analysis may haveinfluenced the results. Furthermore, because of early rec-
ognition and improved care of patients with sepsis, the
survival may have improved in those who were
ADAMTS-13 deficient. Further studies are needed to
better understand the effect of ADAMTS-13 deficiency
on survival of patients.
The study has certain limitations like ADAMTS-13
was only assayed at the time of diagnosis and serial
monitoring was not done so it could not be assessed
whether or not the levels improved with clinical im-
provement of the patient.
We conclude that majority of the patients with severe
sepsis have ADAMTS-13 deficiency that might also play
a role in sepsis-induced thrombocytopenia. It shows that
low ADAMTS-13 does not have a sole diagnostic value
for TTP only but is also low in other disease states like
sepsis. Both TTP and sepsis are associated with throm-
botic microangiopathy and severe ADAMTS-13 defi-
ciency. This raises the possibility of novel therapeutic
strategies for patients with sepsis including plasma infu-
sion; ADAMTS-13 supplementation and synthetic gran-
ulocyte elastase inhibitors. Synthetic granulocyte elastase
inhibitors inhibit granulocyte elastase, an enzyme impli-
cated in causing ADAMTS-13 deficiency in patients
with sepsis. Analysis of ADAMTS-13 in sepsis would
offer help in evaluating the status of the patient. There-
fore, ADAMTS-13 may be used as a diagnostic marker
in patients with sepsis.
Conclusion
Majority of the pediatric patients admitted to hospital
with severe sepsis exhibit ADAMTS-13 deficiency.
ADAMTS-13 deficiency might play a role in sepsis-
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to evaluate the role of ADAMTS-13 deficiency on in-
hospital mortality.
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